Diego Antonio Costa Arantes1, Andréia Souza Gonçalves1, Bruno Correia Jham2, Eliza Carla Barroso Duarte3, Élbio Candido de Paula4, Henrique Moura de Paula5, Elismauro Francisco Mendonça6, Aline Carvalho Batista7. 1. Department of Stomatology (Oral Pathology), Dental School, Federal University of Goiás, Goiânia, Brazil. 2. College of Dental Medicine-Illinois, Midwestern University, Downers Grove, IL, USA. 3. Department of Pathology, School of Medicine, University of Brasília, Brasília, Brazil. 4. Division of Anatomic Pathology, Araújo Jorge Hospital, Association of Cancer Combat of Goiás, Goiânia, Brazil. 5. Division of Anatomic Pathology, Araújo Jorge Hospital, Association of Cancer Combat of Goiás, Goiânia, Brazil; Department of Pathology and Medicine Laboratory, Medicine School, Federal University of Goiás, Goiânia, Brazil. 6. Department of Stomatology (Oral Pathology), Dental School, Federal University of Goiás, Goiânia, Brazil; Head and Neck Division, Araújo Jorge Hospital, Association of Cancer Combat of Goiás, Goiânia, Brazil. 7. Department of Stomatology (Oral Pathology), Dental School, Federal University of Goiás, Goiânia, Brazil. Electronic address: Ali.caba@uol.com.
Abstract
OBJECTIVE: The aim of this study was to investigate the expression of human leukocyte antigens (HLAs) G and E and programmed death-ligand 1 (PD-L1) in oral osteosarcoma (OO) (n = 13). The relationship between the expression of these molecules and histologic grading and metastasis was also evaluated. STUDY DESIGN: HLA-G, HLA-E, and PD-L1 were identified by immunohistochemistry. Samples of normal bone tissue (n = 6) were used as controls. The sections were evaluated using a semiquantitative scoring system with an immunoreactive score, where a score of 0 was considered absent, ≤2 was low, and >2 was high expression. RESULTS: We identified high expression of HLA-G, HLA-E, and PD-L1 by malignant osteoblastic cells in 69.2% of OO cases, which was statistically higher than that in controls (P < .05). Overexpression of these proteins was identified in 8 of 11 samples of high-grade and 1 of 2 samples of low-grade OO. Additionally, 66.6% of patients with metastases (n = 4) and 71.4% of patients without metastases (n = 5) had high expression of HLA-G, HLA-E, and PD-L1 in tumor samples (P > .05). CONCLUSION: OO had high expression of HLA-G, HLA-E, and PD-L1 irrespective of clinicopathologic parameters, including histologic grading and metastasis.
OBJECTIVE: The aim of this study was to investigate the expression of human leukocyte antigens (HLAs) G and E and programmed death-ligand 1 (PD-L1) in oral osteosarcoma (OO) (n = 13). The relationship between the expression of these molecules and histologic grading and metastasis was also evaluated. STUDY DESIGN:HLA-G, HLA-E, and PD-L1 were identified by immunohistochemistry. Samples of normal bone tissue (n = 6) were used as controls. The sections were evaluated using a semiquantitative scoring system with an immunoreactive score, where a score of 0 was considered absent, ≤2 was low, and >2 was high expression. RESULTS: We identified high expression of HLA-G, HLA-E, and PD-L1 by malignant osteoblastic cells in 69.2% of OO cases, which was statistically higher than that in controls (P < .05). Overexpression of these proteins was identified in 8 of 11 samples of high-grade and 1 of 2 samples of low-grade OO. Additionally, 66.6% of patients with metastases (n = 4) and 71.4% of patients without metastases (n = 5) had high expression of HLA-G, HLA-E, and PD-L1 in tumor samples (P > .05). CONCLUSION: OO had high expression of HLA-G, HLA-E, and PD-L1 irrespective of clinicopathologic parameters, including histologic grading and metastasis.